<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7102591\results\search\drug\results.xml">
  <result pre="even for the management of more complex cases of COVID-19." exact="Chloroquine" post="and hydroxychloroquine have now been permanently included, alongside antiviral"/>
  <result pre="the management of more complex cases of COVID-19. Chloroquine and" exact="hydroxychloroquine" post="have now been permanently included, alongside antiviral drugs, in"/>
  <result pre="NSAIDs in the course of viral infections is still controversial." exact="Ibuprofen" post="has been demonstrated to induce an overexpression of ACE2"/>
  <result pre="patients [15]. In addition, the use of both NSAIDs and" exact="acetaminophen" post="could be associated with a masking of the fever"/>
  <result pre="database demonstrated a slightly reduced risk of hospitalized infection for" exact="methotrexate" post="(adjusted RR 0.81, 95% CI 0.70â€&quot;0.93) and hydroxychloroquine (adjusted"/>
  <result pre="infection for methotrexate (adjusted RR 0.81, 95% CI 0.70â€&quot;0.93) and" exact="hydroxychloroquine" post="(adjusted RR 0.74, 95% CI 0.62â€&quot;0.89) [52]. A recent"/>
  <result pre="roughly comparable with bDMARDs [64,65], although these early years of" exact="tofacitinib" post="and baricitinib use have raised the issue of an"/>
  <result pre="risk of Herpes Zoster virus (HZV) infections [66]. Data from" exact="tofacitinib" post="pooled population enrolled in RCTs showed an HZV incidence"/>
  <result pre="that the risk of HZV was higher in patients receiving" exact="tofacitinib" post="compared to those treated with abatacept (aHR 2.01 (95%"/>
  <result pre="2-fold higher versus all bDMARDs [70]. Older age, female sex," exact="prednisone" post="&amp;gt;7.5Â mg/day, prior infection, and greater number of hospitalizations"/>
  <result pre="load and improve disease outcome [77]. In addition, remdesivir, an" exact="adenosine" post="analogue currently under development for the management of Ebola"/>
  <result pre="of anti-rheumatic drugs in COVID-19 infection. Table 1 PROS CONS" exact="Chloroquine" post="Anti-viral effect (increase of endosomal pH required for virus/cell"/>
  <result pre="with terminal glycosylation of the cellular receptor ACE 2) â€&quot;" exact="Hydroxychloroquine" post="IL-6 inhibitors Treatment of cytokine storm manifestations during ARDS"/>
  <result pre="IFNÂ =Â interferon, NSAIDsÂ =Â nonsteroidal anti-inflammatory drugs. 5.1 Chloroquine/hydroxychloroquine" exact="Chloroquine" post="and hydroxychloroquine are widely used anti-malarial drugs with well-known"/>
  <result pre="interferon, NSAIDsÂ =Â nonsteroidal anti-inflammatory drugs. 5.1 Chloroquine/hydroxychloroquine Chloroquine and" exact="hydroxychloroquine" post="are widely used anti-malarial drugs with well-known immunomodulatory properties"/>
  <result pre="to several immuno-rheumatological diseases including RA [83]. The ability of" exact="chloroquine" post="to produce an anti-viral effect has been known since"/>
  <result pre="in vivo experience was controversial [86,87]. At clinically admissible concentrations" exact="chloroquine" post="is able to increase the endosomal pH required for"/>
  <result pre="post-entry stages of the SARS CoV infection. As a consequence," exact="chloroquine" post="has recently been included in at least 10 randomized"/>
  <result pre="Interim results from more than 100 patients have demonstrated that" exact="chloroquine" post="is superior to the control treatment in improving lung"/>
  <result pre="disease course at different levels of severity [92]. More recently," exact="hydroxychloroquine" post="was demonstrated to be more 3-times more potent than"/>
  <result pre="hydroxychloroquine was demonstrated to be more 3-times more potent than" exact="chloroquine" post="in an in vitro study based on pharmacokinetic models"/>
  <result pre="with antiviral drugs such as lopinavir/ritonavir and remdesivir [109]. Interestingly," exact="tofacitinib" post="shows no detectable inhibition of AAK1 [104], whereas currently"/>
  <result pre="blockade in the management of COVID-19 is currently ongoing with" exact="ruxolitinib" post="(ChiCTR2000029580). On the other side, IFN is one of"/>
  <result pre="as being inappropriate for the management of SARS-CoV2 interstitial pneumonia." exact="Chloroquine" post="and hydroxychloroquine are currently included in the treatment protocol"/>
  <result pre="inappropriate for the management of SARS-CoV2 interstitial pneumonia. Chloroquine and" exact="hydroxychloroquine" post="are currently included in the treatment protocol for the"/>
  <result pre="Rheumatol21200788590610.1016/j.berh.2007.06.00217870034 39BoersM.VerhoevenA.C.MarkusseH.M.van de LaarM.A.WesthovensR.van DenderenJ.C.Randomised comparison of combined step-down prednisolone," exact="methotrexate" post="and sulphasalazine with sulphasalazine alone in early rheumatoid arthritisLancet350199730931810.1016/s0140-6736(97)01300-79251634"/>
  <result pre="with sulphasalazine alone in early rheumatoid arthritisLancet350199730931810.1016/s0140-6736(97)01300-79251634 40van EverdingenA.A.JacobsJ.W.G.van ReesemaD.R.S.BijlsmaJ.W.J.Low-dose" exact="prednisone" post="therapy for patients with early active rheumatoid arthritis: clinical"/>
  <result pre="effects: a randomized, double-blindPlacebo-Controlled Clinical Trial Ann Intern Med1362002110.7326/0003-4819-136-1-200201010-00006 41BakkerM.F.JacobsJ.W.G.WelsingP.M.J.VerstappenS.M.M.TekstraJ.TonE.Low-dose" exact="prednisone" post="inclusion in a methotrexate-based, tight control strategy for early"/>
  <result pre="in patients with rheumatoid arthritisJ Rheumatol35200838739318260176 53IbrahimA.AhmedM.ConwayR.CareyJ.J.Risk of infection with" exact="methotrexate" post="therapy in inflammatory diseases: a systematic review and meta-analysisJ"/>
  <result pre="treatmentJ Rheumatol46201871810.3899/jrheum.17136130219772 69CurtisJ.R.XieF.YunH.BernatskyS.WinthropK.L.Real-world comparative risks of herpes virus infections in" exact="tofacitinib" post="and biologic-treated patients with rheumatoid arthritisAnn Rheum Dis7520161843184710.1136/annrheumdis-2016-20913127113415 70PawarA.DesaiR.J.GautamN.KimS.C.Risk"/>
  <result pre="70PawarA.DesaiR.J.GautamN.KimS.C.Risk of admission to hospital for serious infection after initiating" exact="tofacitinib" post="versus biologic DMARDs in patients with rheumatoid arthritis: a"/>
  <result pre="rheumatoid arthritis: a multidatabase cohort studyLancet Rheumatol22020e84e9810.1016/s2665-9913(19)30137-7 71CaporaliR.ZavagliaD.Real-world experience with" exact="tofacitinib" post="for treatment of rheumatoid arthritisClin Exp Rheumatol373201948549530183607 72BiggioggeroM.BeccioliniA.CrottiC.AgapeE.FavalliE.G.Upadacitinib and"/>
  <result pre="inhibits both epidemic and zoonotic coronavirusesSci Transl Med92017eaal365310.1126/scitranslmed.aal3653 80WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="monoclonal 1 antibody blocking SARS-CoV-2 infectionBiorxiv202010.1101/2020.03.11.987958 83SchrezenmeierE.DÃ¶rnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat Rev Rheumatol16202015516610.1038/s41584-020-0372-x32034323 84InglotA.D.Comparison of"/>
  <result pre="randomised, double-blind, placebo controlled trialLancet Infect Dis11201167768310.1016/s1473-3099(11)70065-221550310 87RoquesP.ThibervilleS.-D.Dupuis-MaguiragaL.LumF.-M.LabadieK.MartinonF.Paradoxical effect of" exact="chloroquine" post="treatment in enhancing chikungunya virus infectionViruses10201826810.3390/v10050268 88VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a"/>
  <result pre="and spreadVirol J220056910.1186/1743-422x-2-6916115318 89DevauxC.A.RolainJ.-M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
  <result pre="of chloroquineLancet Infect Dis62006676910.1016/s1473-3099(06)70361-916439323 91Chinese Clinical Trial Registry. 2020. 92GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
  <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 </snippets>
</snippetsTree>
